Ones To Watch News
Refine search
Pharmaceutical
Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma advancing a new kind of pain medicine, has announced novel data presented for its lead investigational therapy, cebranopadol, at PAINWeek 2026, taking place September 8-11 in Las Vegas, USA. 11 September 2026
Biotechnology
US clinical-stage biotech Tyra Biosciences yesterday announced initial results from SURF302, its Phase II study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). 10 September 2026
Biotechnology
US biotech Evommune has said its oral MRGPRX2 antagonist EVO756 failed to meet its primary or secondary endpoints in a Phase IIb trial in moderate-to-severe atopic dermatitis (AD), and that it does not plan to advance the candidate further in the indication. 10 September 2026
Biotechnology
USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. 10 September 2026
Biotechnology
UK clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as chief medical officer (CMO) to accelerate the clinical development of the company’s pipeline of highly novel antibody therapeutics. 10 September 2026
Biotechnology
Netherlands-based Scenic Biotech, a company developing therapies that restore lysosomal function in neurodegenerative disease, has appointed Judith Walker as chief medical officer, as the firm prepares to move its lead program into the clinic in early 2027. 10 September 2026
Biotechnology
US clinical stage biotech Callio Therapeutics has announced the appointment of Zachary (Zach) Hornby as chief executive (CEO). 10 September 2026
Pharmaceutical
US biotech company TwoStep Therapeutics has secured Food and Drug Administration (FDA) clearance to begin human testing of its lead cancer candidate, TS-104, alongside an oversubscribed $62.5 million series A financing. The San Carlos, California-based firm said patient enrollment in a first-in-human Phase I trial should begin before the end of the year. 10 September 2026
Biotechnology
US biotech company Encoded Therapeutics has closed a $275 million series F financing that will fund pivotal testing of ETX101, a gene therapy for Dravet syndrome, a severe form of childhood epilepsy. The privately held South San Francisco firm announced the round on Wednesday, days after presenting updated trial data at the European Epilepsy Congress. 10 September 2026
Biotechnology
NodThera, the US biotech developing oral NLRP3 inhibitors, has renamed itself Rezera and announced plans to advance its lead candidate, ruvonoflast, into a Phase III trial in peripheral artery disease (PAD) in the first half of 2027, alongside positive topline data from a Phase II study of the drug. 9 September 2026
Biotechnology
US biotech Kura Oncology today announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. 9 September 2026
Pharmaceutical
An artificial intelligence reading of lung scans from a mid-stage trial of Endeavor BioMedicines' taladegib has found that the experimental drug improved the physical structure of the lungs in idiopathic pulmonary fibrosis (IPF), an effect its developers argue standard breathing tests capture only in part. 9 September 2026
Biotechnology
Swedish biologics company Simris Group has settled on amanitin as the basis of its antibody-drug conjugate work, and says it intends to take two proprietary programs into clinical development by late 2027 or early 2028. 9 September 2026
Pharmaceutical
US targeted cardiometabolic therapeutics company Sparrow Pharmaceuticals has announced the appointment of George Eldridge as chief financial officer (CFO). 9 September 2026
Biotechnology
US biopharma Inhibrx Biosciences has reported that its OX40 agonist INBRX-106, combined with Merck & Co's Keytruda (pembrolizumab) nearly doubled response rates against pembrolizumab alone in a randomized Phase II trial in head and neck squamous cell carcinoma (HNSCC). 9 September 2026
Pharmaceutical
New Jersey, USA-based precision oncology company PMV Pharmaceuticals today announced the appointment of Philip Herman as chief commercial officer (CCO). 9 September 2026
Biotechnology
US biotech Moonwalk Biosciences, which is developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing. 8 September 2026
Biotechnology
US clinical-stage biotech PDS Biotechnology saw its shares rocket 183% to $0.62 today, after it announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (PIPE) transaction. 8 September 2026
Biotechnology
Germany-based contract development and manufacturing firm ProBioGen and French biotech Transgene announced that the companies have broadened the scope of their existing collaboration. 8 September 2026
Biotechnology
UK biotech Cytospire Therapeutics, which is developing differentiated multispecific immune cell engager antibodies, today announces the appointment of Dr Sumeet Ambarkhane as chief medical officer (CMO). 8 September 2026
Biotechnology
USA-based cell therapy company Legend Biotech has named Alan Bash as interim chief executive after Ying Huang stepped down from the role and resigned from the board. 28 July 2026
Biotechnology
US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep apnea (OSA) therapy, Oxnimbi (AD109). 28 July 2026
Biotechnology
Biotech company Capricor Therapeutics faces heightened regulatory uncertainty after US Food and Drug Administration (FDA) reviewers questioned whether its resubmitted Biologics License Application for deramiocel provides substantial evidence of effectiveness in cardiomyopathy in male patients with Duchenne muscular dystrophy. 28 July 2026
Biotechnology
Spruce Biosciences has appointed Dr Adrian Quartel as chief medical officer (CMO), effective immediately. 28 July 2026
Biotechnology
Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed special purpose acquisition company (SPAC) Research Alliance Corporation III. 27 July 2026
Biotechnology
Shares of US biotech Forte Biosciences shot up nearly 40% to $76.40 in early trading, on the news of a takeover bid from Belgo-Dutch immunology specialist argenx. 27 July 2026
Pharmaceutical
Men’s health specialist Androlabs has expanded its European commercial presence through a partnership with Laboratoires Majorelle to market Testavan (testosterone) in France. 27 July 2026
Biotechnology
Sino-American oncology-focused biotech BeOne Medicines’ announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell. This brings total US manufacturing investment to more than $1 billion. 24 July 2026
Biotechnology
French biotech Abivax has hired four senior commercial executives, filling out its leadership bench as it prepares to sell its experimental bowel disease drug obefazimod (ABX464) in the USA. The appointments come ahead of a planned New Drug Application to the US FDA, which the company expects to file in the fourth quarter of 2026. 24 July 2026
Pharmaceutical
US RNA medicines company Arrowhead Pharmaceuticals saw its shares rise about 19% after reporting positive top-line results from two pivotal Phase III studies of plozasiran in severe hypertriglyceridemia (sHTG). 23 July 2026
Pharmaceutical
A young California start-up wants to do for drug development what enterprise software did for accounting and sales: put the whole thing in one connected system. Cheiron, based in Los Altos, has raised $8 million in seed funding to build what it calls an AI-native operating system for drug programs. 23 July 2026
Pharmaceutical
USA-based gout specialist Crystalys Therapeutics has closed an oversubscribed $130 million series B financing to fund late-stage global development and commercial preparation for its lead drug dotinurad, an oral URAT1 inhibitor. The San Diego biotech, which is still built around this single asset, raised the money less than a year after a $205 million series A. 23 July 2026
Biotechnology
US clinical-stage biotech Kairos Pharma saw its shares close down 12.6% at $0.31 yesterday, despite announcing a strategic collaboration with German pharma major Bayer. 23 July 2026
Pharmaceutical
BridgeBio Pharma has moved closer to bringing a first targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1) to market after the US Food and Drug Administration (FDA) accepted its New Drug Application for encaleret. 22 July 2026
Biotechnology
US AI-native pharma company Formation Bio today announced the appointment of Dr Michael Ehlers as chief scientific officer (CSO) and head of R&D. 22 July 2026
Biotechnology
USA-based biotech ARScience Biotherapeutics has begun a technology transfer for low-dose interleukin-2 (LD IL-2), as it prepares to scale manufacturing ahead of potential later-stage development and commercialization. 22 July 2026
Biotechnology
US immunology specialist Celldex yesterday reported mixed top-line results from the company’s Phase II study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. 22 July 2026
Pharmaceutical
Cambridge, USA-based Agios Pharmaceuticals’ shares fell as much as 14% today after the company announced it would discontinue development of tebapivat in sickle cell disease following Phase II trial results. 21 July 2026
Biotechnology
Swiss contract development and manufacturing organization (CDMO) Lonza and Engitix, a UK-based ECM-based drug discovery and development firm, today announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs) and deliver life-changing therapies for patients with chronic diseases. 21 July 2026
Biotechnology
Germany’s Allogenetics today announced the appointment of Dr Jeroen Rovers as chief medical officer (CMO). 21 July 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze